Vor Bio Reports Successful Telitacicept Kidney Trial Results
Final two-year data confirm telitacicept significantly slows kidney function decline in IgA nephropathy patients.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Should the government prioritize funding for new clinical trials that target chronic kidney diseases?
Vor Bio announced final 104-week results from its Phase 3 TELIGAN trial, demonstrating that telitacicept slows the decline of kidney function in adults with IgA nephropathy. The study showed that patients treated with the drug experienced significantly better outcomes compared to those who received a placebo.
Why it matters
The study validates the drug's mechanism of dual BAFF/APRIL inhibition in addressing autoimmune-driven kidney disease. By reducing autoreactive B cells and autoantibody production, the treatment offers a potential path to preventing kidney failure.
The study enrolled 318 adults receiving 240 mg subcutaneous doses, achieving a 60.3% reduction in urine protein-to-creatinine ratio and a 47.79% decrease in serum galactose-deficient IgA1. While 95% of patients reported adverse events, 56% specifically experienced injection-site reactions.
The players
Vor Bio
A clinical-stage biopharmaceutical company focused on developing novel therapies to treat complex autoimmune and kidney diseases.
American Society of Nephrology
A global professional organization dedicated to the study and treatment of kidney diseases through research and medical education.
The details
Participants were randomized to receive 240 mg of the drug or a placebo via subcutaneous injection, administered weekly through Week 39 and bi-weekly thereafter. No patients in the telitacicept group experienced a prespecified composite kidney failure event throughout the two-year duration.
Timeline
May 2026: 39-week study results were published.
June 2026: Telitacicept received conditional approval in China.
October 22, 2026: Final 104-week trial results were presented at the American Society of Nephrology Kidney Week.
The Tech Race
This development aligns with the American Society of Nephrology Kidney Week 2026 reporting standards, marking a significant milestone in modern immunotherapy research. It reflects a shift toward dual-target biological agents, moving away from broader immunosuppressive treatments that often carry higher toxicity risks.
For patients with IgA nephropathy, this data signals a move toward targeted therapies that could replace traditional, less specific medications. Clinicians will now have a clearer understanding of the efficacy and safety profile of subcutaneous telitacicept when considering long-term treatment plans.
The takeaway
The study demonstrates that dual-target inhibition successfully mitigates the progression of kidney disease over two years. Patients and physicians should discuss the specific frequency of injection-site reactions as part of evaluating the therapy's safety profile.
What happens next
Vor Bio has confirmed plans to initiate global Phase 3 clinical trials for the application of telitacicept in the treatment of myasthenia gravis and Sjögren's disease.
Further reading
Learn more about ongoing advancements in this field by visiting our Biotech section.
Live Poll
Should the government prioritize funding for new clinical trials that target chronic kidney diseases?
